Alderley Park is a place where world leading science, innovation and stylish living come together to create a place like no other.
Part of Bruntwood SciTech, a 50:50 joint venture between leading property company Bruntwood and Legal and General, Alderley Park is currently undergoing £247m investment. Home to the internationally-recognised Mereside bioscience campus, the Park offers more than 1m sq ft of high specification lab space, a range of scientific services and an accelerator delivering a comprehensive programme of business support for start-ups and scale-ups. It is also home to a vibrant and fast growing community of over 60 established and 150 pre-start up companies.
The newly re-developed 150,000 sq ft ‘Glasshouse’, opened in February 2020, offers high specification, collaborative workspace to tech companies and forward thinking, innovative businesses.
The Park is also home to a wide range of amenities including a conference centre complete with a 232 seat auditorium and meeting rooms, restaurant, gym and outdoor sports pitches. It also offers unrivalled 100GB connectivity, Enterprise Zone status, and is part of the Cheshire Science Corridor.
This is a place where people can live connected lives, in a community that will shape its own future. A place to do science, do business, work We can help you shape the future. and live differently, with no boundaries. Where people, work, life, ideas and conversations flow seamlessly together.
Nowhere else offers you so much room to breathe and space to think. Or such a canvas for being creative, individual and inventive.
If you believe that things don’t always have to be done the way people have always done them, if you want to keep evolving the way you do business, work and live, you’ll find Alderley Park a breath of fresh air.
Shift Bioscience Ltd
Shift Bioscience is a biotech startup targeting the root causes of aging to extend healthy lifespan
Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Sygnature Discovery is a leading independent integrated drug discovery and pre-clinical services CRO. Founded in 2004 and private equity-backed since 2017, we operate a fully-enabled research facility in Nottingham, UK, housing nearly 400 staff (80% of our scientists have PhDs). Our experienced R&D scientists possess all the professional skills and know-how required to undertake the most demanding of drug discovery and/or pre-clinical development projects and drive them from target validation, through hit identification, hit-to-lead and lead optimization to development candidate. Sygnature collaborates with its partners via risk share and FTE-based collaborations.